File | Jotup

Vision Sensing Acquisition Corp. Receives Positive Ruling from Nasdaq Hearings Panel

Retrieved on:

Friday, April 19, 2024

Language, Hearing, Security (finance), Form 10-Q, Exchange, VSAC, Letter, Form, Panel, Acquisition, Venture round, Series, File, Cryptocurrency

On January 23, 2024, the Company submitted an appeal to the appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

Key Points:

On January 23, 2024, the Company submitted an appeal to the appeal Staff’s determination to a Hearings Panel (the “Panel”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.
This submission included a detailed Compliance Plan, to present to the Panel, to regain compliance with the Listing Rules and also requested a stay of the suspension of the Company’s securities.
On January 24, 2024, the Company was notified, by the Nasdaq Hearings Advisor, that the hearing is scheduled to be held on April 4, 2024.
The Company intends to vigorously pursue its plan to return to compliance with the Nasdaq listing criteria on or prior to July 15, 2024.

EVe Mobility Acquisition Corp Receives NYSE Notice Regarding Late Filing of Annual Report on Form 10-K

Retrieved on:

Friday, April 19, 2024

Delinquent, Annual report, Security (finance), Exchange, File, Acquisition, Bank statement, Medical device

Reference is made to the Company’s Notification of Late Filing on Form 12b-25 (filed with the SEC on March 27, 2024) as amended through the filing of a Form 12b-25/A with the SEC on April 15, 2024, which describe the circumstances leading to the late filing of the Delinquent Report.

Key Points:

Reference is made to the Company’s Notification of Late Filing on Form 12b-25 (filed with the SEC on March 27, 2024) as amended through the filing of a Form 12b-25/A with the SEC on April 15, 2024, which describe the circumstances leading to the late filing of the Delinquent Report.
Additional time is needed by the Company to complete its review of the financial statements included in the Delinquent Report to ensure a complete, accurate Delinquent Report.
The Company intends to file the Delinquent Report as soon as practicable and in any event within the six-month period.
If the Company fails to file the Delinquent Report during the Initial Cure Period, the Exchange may, in its sole discretion, grant an up to six-month additional cure period (the "Additional Cure Period").

POWERFLEET ALERT: Bragar Eagel & Squire, P.C. is Investigating PowerFleet, Inc. on Behalf of PowerFleet Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Friday, April 19, 2024

News, Annual report, PowerFleet, P.C, Bank statement, Telephone, File, Calendar, Cryptocurrency

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against PowerFleet, Inc. (“PowerFleet” or the “Company”) (NASDAQ: PWFL) on behalf of PowerFleet stockholders.

Key Points:

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against PowerFleet, Inc. (“PowerFleet” or the “Company”) (NASDAQ: PWFL) on behalf of PowerFleet stockholders.
Our investigation concerns whether PowerFleet has violated the federal securities laws and/or engaged in other unlawful business practices.
PowerFleet also disclosed that it "expect[s] to report a material weakness" in internal control over financial reporting.
On this news, PowerFleet's stock price fell $0.31 per share, or 6.54%, to close at $4.43 per share on April 8, 2024.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

Friday, April 19, 2024

Sickle cell disease, FDA, Cancer, DSM-IV codes, SCD, News, Food, Blue, Complaint, Class, Bluebird bio, History, Patient, Court, BLA, File, Biotechnology, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points:

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Top Wealth Group Holding Limited Announces Closing of Initial Public Offering

Retrieved on:

Friday, April 19, 2024

File, Sale, Prospectus, Offering, Suite, Lexington Avenue, Form, Marketing, Telephone, Cryptocurrency

Hong Kong, April 18, 2024 (GLOBE NEWSWIRE) -- Top Wealth Group Holding Limited (the “Company” or “Top Wealth”), a Hong Kong-based supplier of luxury caviar products, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share.

Key Points:

Hong Kong, April 18, 2024 (GLOBE NEWSWIRE) -- Top Wealth Group Holding Limited (the “Company” or “Top Wealth”), a Hong Kong-based supplier of luxury caviar products, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a public offering price of US$4.00 per ordinary share.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price after the closing of the Offering, less underwriting discounts.
Proceeds from the Offering will be used for expanding the Company’s business internationally, brand promotion and marketing, and general working capital.
In addition, copies of the prospectus and free writing prospectus relating to the Offering may be obtained via the SEC’s website at www.sec.gov .

Mingteng International Corporation Inc. Announces Pricing of Initial Public Offering

Retrieved on:

Thursday, April 18, 2024

File, Sale, Prospectus, Offering, Oak Street, Research, Form, Security (finance)

Wuxi, China, April 18, 2024 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (the “Company” or “Mingteng International”), an automotive mold developer and supplier in China, today announced the pricing of its initial public offering (the “Offering”) of 1,275,000 ordinary shares, 1,050,000 of which are being offered by the Company and 225,000 by a selling shareholder, at a public offering price of US$4.00 per ordinary share.

Key Points:

Wuxi, China, April 18, 2024 (GLOBE NEWSWIRE) -- Mingteng International Corporation Inc. (the “Company” or “Mingteng International”), an automotive mold developer and supplier in China, today announced the pricing of its initial public offering (the “Offering”) of 1,275,000 ordinary shares, 1,050,000 of which are being offered by the Company and 225,000 by a selling shareholder, at a public offering price of US$4.00 per ordinary share.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 157,500 ordinary shares at the public offering price, less underwriting discounts.
The Offering is expected to close on or about April 22, 2024, subject to the satisfaction of customary closing conditions.
In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC's website at www.sec.gov .

Intra-Cellular Therapies Prices Public Offering of Common Stock

Retrieved on:

Thursday, April 18, 2024

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.

Key Points:

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions.
J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, April 18, 2024

Copper, Sickle cell disease, FDA, Cancer, Elivaldogene autotemcel, DSM-IV codes, SCD, News, Food, Truist, Blue, Complaint, Class, Barclays, Meta, History, P.C, Patient, Defendant, False, Health, Medicare, NBH, BLA, Metamaterial, File, Biotechnology, Disclosure, Cryptocurrency

In return, agilon takes on the responsibility of managing the total cost and quality of care for those patients.

Key Points:

In return, agilon takes on the responsibility of managing the total cost and quality of care for those patients.
This model incentivizes agilon and its contracted physician partners to focus on preventive care and improve health outcomes in order to control costs.
If the total cost of caring for patients is less than the fixed payments agilon receives, it realizes a profit.
On this news, agilon’s stock price fell $2.23, or 13.2 percent, to close at $14.66 on November 3, 2023.

BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline

Retrieved on:

Thursday, April 18, 2024

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.

Key Points:

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023.
Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Junee Limited Announces Pricing of $8 Million Initial Public Offering

Retrieved on:

Wednesday, April 17, 2024

File, Sale, Prospectus, LLP, Offering, Form, Attention, Security (finance)

Hong Kong, April 17, 2024 (GLOBE NEWSWIRE) -- Junee Limited (the “Company” or “Junee”), a provider of interior design, fit-out and maintenance services in Hong Kong, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a price of $4.00 per share.

Key Points:

Hong Kong, April 17, 2024 (GLOBE NEWSWIRE) -- Junee Limited (the “Company” or “Junee”), a provider of interior design, fit-out and maintenance services in Hong Kong, today announced the pricing of its initial public offering (the “Offering”) of 2,000,000 ordinary shares at a price of $4.00 per share.
The Company expects to receive aggregate gross proceeds of $8 million from the Offering, before deducting underwriting discounts and other related expenses.
The Offering is expected to close on or about April 19, 2024, subject to the satisfaction of customary closing conditions.
In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 ordinary shares at the public offering price, less underwriting discounts.